FI80694B - Foerfarande foer framstaellning av teraoeutiskt aktiva 5,6,7,8-tetrahydroimidazo/1,5-a/pyridiner. - Google Patents
Foerfarande foer framstaellning av teraoeutiskt aktiva 5,6,7,8-tetrahydroimidazo/1,5-a/pyridiner. Download PDFInfo
- Publication number
- FI80694B FI80694B FI852399A FI852399A FI80694B FI 80694 B FI80694 B FI 80694B FI 852399 A FI852399 A FI 852399A FI 852399 A FI852399 A FI 852399A FI 80694 B FI80694 B FI 80694B
- Authority
- FI
- Finland
- Prior art keywords
- formula
- compound
- reacted
- hydrogen
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Claims (4)
1. Förfarande för framställning av terapeutiskt aktiva 5,6,7,8-tetrahydroimidazo[l,5-a]pyridiner med formeln I* < 7 / \=.l ‘W ·' · IN \/ i, i vilken formel Rj^ betecknar cyano, halogen, C1-C4-alkyl el-ler amino och R2 betecknar väte, fenyl-Cj-C^-alkyl, C^-C^-alkyltio eller C1-C4-alkoxikarbonyl, och deras stereoisome-rer, blandningar av stereoisomerer eller farmaceutiskt god-tagbara salter, kännetecknat därav, att d) en förening med formeln V / \ h* (y) • r · I II 'V' i. i vilken Rj^ och R2 betecknar detsamma som ovan i formeln I* och är halogen, omsätts med en bas, eller e) en förening med formeln VI 65 8 0 6 9 4 /X . I*’ · (VI) /\ I II ‘v./’ L i vilken formel och R2 betecknar detsamma som ovan i for-meln I* och X2 är halogen, omsätts med en bas, eller f) 1 en förenlng med formeln vii / \ • · 3SSSE2 · \A> • · ** \ (VII) / \ • · I II V i,· i vilken Rj' är en i en cyanogrupp överförbar grupp och R2 betecknar detsamma som ovan i formeln I*, ' överförs i en cyanogrupp med en av de följande överföringsreaktionerna: (1) en förenlng med formeln VII, väri Rj' är formyl, omsätts med hydrazinsyra, eller (2) en förening med formeln VII, väri R1' är karbamoyl eller Cj-^-alkylkarbamoyl, omsätts med ett dehydratiseringsmedel, eller g) en förening med formeln IX 66 8 0 6 9 4 A._. ϊ=° HÄX Jl (IX ) y \ I II V i. i vilken R-j^ betecknar detsamma som ovan i formeln I*, om-sätts i närvaro av ett reducerande medel, eller h) en förening med formeln Vllc / \ __ ^00H (Vllc) I II V k, i vilken och R2 betecknar detsamma som ovan i formeln I*, dekarboxyleras, eller i) en förening med formeln I /\=. \A./* y\ <*> I n V’ t> eller ett 7,8-dihydroderivat därav, väri betecknar det- II 67 80694 samma som ovan i formeln I* eller Mr hydroximetyl, reduceras eventuellt genom att reducera samtidigt substituenten R^_ = CH2OH till gruppen = CH3; och/eller (1) för framställning av en förening med formeln I*, väri R2 Sr väte, en förening med formeln I*, väri R2 är C-l-C^-alkoxikarbonyl, omsätts först med natriumhydroxid och sedan med klorvätesyra; (2) för framställning av en förening med formeln I*, väri R2 är C^-C^-alkyltio, den motsvarande föreningen med formeln I*, väri R2 är väte, omsätts med di-C1-C4-alkyldisulfid; (3) för framställning av en förening med formeln I*, väri R2 är C1-C4-alkoxikarbonyl, den motsvarande föreningen med formeln I*, väri R2 är väte, omsätts med C1-C4-alkylhalogenfor-miat; (4) för framställning av en förening med formeln I*, väri R! är amino, den motsvarande föreningen med formeln I*, väri Rj^ är karboxi, omsätts med hydrazinsyra; (5) för framställning av en förening med formeln I*, väri R2 är fenyl-Cj-C^-alkyl, den motsvarande föreningen med formeln I*, väri R2 är väte, omsätts med fenyl-C1-C4-alkylhalogenid; (6) för framställning av en förening med formeln I*, väri Rj är cyano, den motsvarande föreningen med formeln I*, väri Rx är halogen, omsätts med ett cyanidsalt; (7) för framställning av en förening med formeln I*, väri Rj^ är cyano, den motsvarande föreningen med formeln I*, väri R1 är amino, omsätts först med ett alkalinitritsalt och sedan med koppar(I)cyanid; och/eller ett erhället sait överförs i en fri förening eller ett annat sait och/eller en fri förening överförs i ett sait 68 80694 och/eller en enantiomerisk blandning, säsom ett racemat, uppdelas i optiska isomerer.
2. Förfarande för framställning av terapeutiskt aktiva 5,6,7,8-tetrahydroimidazo[l,5-a]pyridiner med formeln Ib i 7 /\ = .l '\λ> ·' · I II V tl i vilken formel Rj betecknar cyano eller C1-C4-alkyl och R2 är väte, fenyl-C1-C4-alkyl eller C1-C4-alkyltio, stereoiso-merer, blandningar av stereoisomerer eller farmaceutiskt godtagbara salter av dessa föreningar, känneteck-n a t därav, att d) en förening med formeln Vb · · / \ • · =S5 · x>4h/</ Λ (Vb) • · I H ’V* k i vilken Rx betecknar detsamma som ovan i formeln Ib och X1 Sr halogen, omsätts med en bas, eller e) en förening med formeln VIb li 69 80694 /\_. • · |V (VIb) /\ ι' · I ιι V’ il i vilken formel R-j^ och R2 betecknar detsamma som ovan i formeln Ib och X2 är halogen, omsätts med en bas, eller f) 1 en förening med formeln Vllb / \ • »SSSS5· • · R* \ (Vllb) S \ I N V* i»· i vilken R!' är en grupp eller rest, som kan överföras i en cyanogrupp och R2 betecknar detsamma som ovan i formeln Ib, R2' överförs i cyano med en av de följande överföringsreak-tionerna: (1) en förening med formeln Vllb, väri ' är halogen, omsätts med ett cyanidsalt, (2) en förening med formeln Vllb, väri R^' är karbamoyl eller C^-C^-alkylkarbamoyl, omsätts med ett starkt dehydra-tiseringsmedel, (3) en förening med formeln Vllb, väri är formyl, omsätts med hydrazinsyra, eller 70 80694 (4) en förening med formeln Vllb, väri R^' är amino, omsätts först med ett alkalinitritsalt och sedan med koppar(I)cya-nid, eller i) en förening med formeln Ia 7 / \==.» I II V* i. eller ett 7,8-dihydroderivat därav reduceras med väte i när-varo av en hydreringskatalysator och/eller (1) för framställning av en förening med formeln Ib, väri R2 är C1-C4-alkyltio, den motsvarande föreningen med formeln Ib, väri R2 är väte, omsätts med di-C^-C^-alkyldisulfid, och/eller ett erhället sait överförs i en fri förening eller ett annat sait och/eller en fri förening med en saltbildande grupp i ett sait och/eller en erhällen racemisk blandning uppdelas i enskilda enantiomerer.
3. Förfarande enligt patentkravet 1, känneteck- n a t därav, att man framställer 5-(p-cyanofenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridin, eller ett farmaceutiskt godtagbart syraadditionssalt därav
4. Förfarande enligt patentkravet 2, känneteck- n a t därav, att man framställer 5-(p-cyanofenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridin, eller ett farmaceutiskt godtagbart syraadditionssalt därav. il
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI882863A FI83079C (sv) | 1984-06-20 | 1988-06-15 | Förfarande för framställning av terapeutiskt aktiva 5-fenyl-imidazo/1, 5-a/pyridiner |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/622,421 US4617307A (en) | 1984-06-20 | 1984-06-20 | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US62242184 | 1984-06-20 |
Publications (4)
Publication Number | Publication Date |
---|---|
FI852399A0 FI852399A0 (fi) | 1985-06-17 |
FI852399L FI852399L (fi) | 1985-12-21 |
FI80694B true FI80694B (fi) | 1990-03-30 |
FI80694C FI80694C (sv) | 1990-07-10 |
Family
ID=24494112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI852399A FI80694C (sv) | 1984-06-20 | 1985-06-17 | Förfarande för framställning av terapeutiskt aktiva 5,6,7,8-tetrahydro imidazo/1,5-a/pyridiner |
Country Status (31)
Country | Link |
---|---|
US (1) | US4617307A (sv) |
EP (1) | EP0165904B1 (sv) |
JP (1) | JPS6112688A (sv) |
KR (1) | KR900008566B1 (sv) |
AT (1) | ATE62415T1 (sv) |
AU (1) | AU589565B2 (sv) |
BG (7) | BG60262B2 (sv) |
CA (1) | CA1276633C (sv) |
CS (1) | CS268672B2 (sv) |
CY (1) | CY1750A (sv) |
DD (1) | DD237510A5 (sv) |
DE (1) | DE3582452D1 (sv) |
DK (1) | DK170302B1 (sv) |
DZ (1) | DZ799A1 (sv) |
ES (6) | ES8702406A1 (sv) |
FI (1) | FI80694C (sv) |
GR (1) | GR851487B (sv) |
HK (1) | HK23494A (sv) |
HU (1) | HU202529B (sv) |
IE (1) | IE58070B1 (sv) |
IL (1) | IL75546A (sv) |
MA (1) | MA20459A1 (sv) |
MX (1) | MX9203369A (sv) |
NO (1) | NO162467C (sv) |
NZ (1) | NZ212483A (sv) |
PH (1) | PH23390A (sv) |
PL (6) | PL145814B1 (sv) |
PT (1) | PT80661B (sv) |
RO (1) | RO92583A (sv) |
SU (6) | SU1433413A3 (sv) |
ZA (1) | ZA854615B (sv) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5428160A (en) * | 1982-12-21 | 1995-06-27 | Ciba-Geigy Corporation | Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives |
US4728645A (en) * | 1982-12-21 | 1988-03-01 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors |
US4889861A (en) * | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
GB8510541D0 (en) * | 1985-04-25 | 1985-05-30 | Wyeth John & Brother Ltd | Heterocyclic compounds |
US5171858A (en) * | 1985-06-05 | 1992-12-15 | Schering A.G. | Preparation of certain 5,6-dihydro-8-phenyl-imidazo[1,5-a]pyridines |
US4978672A (en) * | 1986-03-07 | 1990-12-18 | Ciba-Geigy Corporation | Alpha-heterocyclc substituted tolunitriles |
US4749713A (en) * | 1986-03-07 | 1988-06-07 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
US4937250A (en) * | 1988-03-07 | 1990-06-26 | Ciba-Geigy Corporation | Alpha-heterocycle substituted tolunitriles |
US4797411A (en) * | 1986-07-18 | 1989-01-10 | Farmitalia Carlo Erba S.P.A. | Cycloalkyl-substituted 4-pyridyl derivatives and use as aromatase inhibitors |
GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
US5066656A (en) * | 1989-11-01 | 1991-11-19 | Janssen Pharmaceutica N.V. | Pharmacologically active (6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1H-benzotriazole derivatives |
MTP1076B (en) * | 1990-01-12 | 1991-09-30 | Ciba Geigy Ag | Hemihydrate |
US5162337A (en) * | 1990-10-05 | 1992-11-10 | Merck & Co., Inc. | Animal growth promotion |
CA2066369A1 (en) * | 1991-04-19 | 1992-10-20 | Alex Elbrecht | Control of sex differentiation in fish |
CH683151A5 (de) * | 1991-04-24 | 1994-01-31 | Ciba Geigy Ag | Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus. |
JPH05176659A (ja) * | 1991-04-26 | 1993-07-20 | Merck & Co Inc | 家禽における雌性表現型を転換するために抗ミュラー管ホルモンを単独またはアロマターゼ阻害剤と組合せて使用する方法 |
AU2356195A (en) * | 1994-04-14 | 1995-11-10 | Sepracor, Inc. | Treating estrogen-dependent diseases with (-)-fadrozole |
CA2150326A1 (en) * | 1994-05-27 | 1995-11-28 | Kimihiro Murakami | Azolyl methyl phenyl derivatives having aromatase inhibitory activity |
DE4432106A1 (de) * | 1994-09-09 | 1996-03-14 | Hoechst Ag | Mit Heterocyclen-N-Oxid-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum, sie enthaltendes Medikament sowie Zwischenprodukte zu ihrer Herstellung |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US6858598B1 (en) | 1998-12-23 | 2005-02-22 | G. D. Searle & Co. | Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
ATE345790T1 (de) * | 2002-07-30 | 2006-12-15 | Novartis Pharma Gmbh | Kombination von einem aromatasehemmer mit einem bisphosphonat |
ATE335744T1 (de) * | 2002-08-07 | 2006-09-15 | Novartis Pharma Gmbh | Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen |
US7223866B2 (en) * | 2002-11-18 | 2007-05-29 | Novartis Ag | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases |
WO2005007627A1 (ja) * | 2003-07-18 | 2005-01-27 | Nihon Nohyaku Co., Ltd. | フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤 |
GB0327839D0 (en) | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
US20080161321A1 (en) | 2004-03-17 | 2008-07-03 | David Louis Feldman | Use of Renin Inhibitors in Therapy |
US20080076784A1 (en) * | 2004-05-28 | 2008-03-27 | Peter Herold | Bicyclic, Nitrogen-Containing Heterocycles and Aromatase Inhibitors |
CA2568165A1 (en) * | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
US20100240641A1 (en) * | 2006-05-26 | 2010-09-23 | Julien Papillon | Aldosterone Synthase and/or 11B-hydroxylase Inhibitors |
PL2049517T3 (pl) | 2006-07-20 | 2014-06-30 | Novartis Ag | Pochodne amino-piperydyny jako inhibitory CETP |
WO2008027284A1 (en) * | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
EP2120938A4 (en) * | 2006-12-20 | 2010-12-08 | Merck Sharp & Dohme | IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES |
EA022912B1 (ru) | 2007-11-05 | 2016-03-31 | Новартис Аг | Производные 4-бензиламино-1-карбоксиацилпиперидина как ингибиторы бпхэ (белка-переносчика холестерилового эфира), применимые для лечения заболеваний, таких как гиперлипидемия или артериосклероз |
CA2707651A1 (en) | 2007-12-03 | 2009-06-11 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
EP2095819A1 (en) * | 2008-02-28 | 2009-09-02 | Maastricht University | N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors |
JP5466759B2 (ja) | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
CN103896796B (zh) | 2009-05-28 | 2016-04-27 | 诺华股份有限公司 | 作为脑啡肽酶抑制剂的取代的氨基丙酸衍生物 |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
AR086665A1 (es) | 2011-06-14 | 2014-01-15 | Lilly Co Eli | Inhibidor de aldosterona sintasa y composiciones farmaceuticas |
AU2012282109B2 (en) | 2011-07-08 | 2016-06-23 | Novartis Ag | Method of treating atherosclerosis in high triglyceride subjects |
SG11201404061YA (en) | 2012-01-17 | 2014-08-28 | Novartis Ag | New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
NZ710574A (en) | 2013-02-14 | 2017-11-24 | Novartis Ag | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
EA201690278A1 (ru) | 2013-07-25 | 2016-06-30 | Новартис Аг | Циклические полипептиды для лечения сердечной недостаточности |
CA2918077A1 (en) | 2013-07-25 | 2015-01-29 | Novartis Ag | Bioconjugates of synthetic apelin polypeptides |
MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
MX2017009839A (es) * | 2015-01-29 | 2017-11-02 | Novartis Ag | Proceso para la produccion de derivados de imidazolo condensados. |
GB201511790D0 (en) | 2015-07-06 | 2015-08-19 | Iomet Pharma Ltd | Pharmaceutical compound |
JP2016074729A (ja) * | 2015-12-31 | 2016-05-12 | 国立大学法人 千葉大学 | イミダゾリウム塩及びそれを用いた不斉合成触媒並びにイミダゾリウム塩の製造方法 |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
WO2018078049A1 (en) | 2016-10-27 | 2018-05-03 | Damian Pharma Ag | Aldosterone synthase inhibitor |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
WO2019211394A1 (en) | 2018-05-03 | 2019-11-07 | Damian Pharma Ag | R-fadrozole for use in the treatment of aldostonerism |
US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
EP3887388A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5124517B1 (sv) * | 1971-03-15 | 1976-07-24 | ||
FR2449689A1 (fr) * | 1979-02-20 | 1980-09-19 | Logeais Labor Jacques | Nouveaux derives condenses de pyrrolidine ou de piperidine, leur procede de preparation et leurs applications en therapeutique |
US4444775A (en) * | 1981-06-22 | 1984-04-24 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridines |
CA1250844A (en) * | 1981-06-22 | 1989-03-07 | Neville Ford | Substituted imidazo¬1,5-a|pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application |
US4409226A (en) * | 1981-10-05 | 1983-10-11 | Schering Corporation | Imidazo[1,5-a]pyridines |
US4361567A (en) * | 1981-10-05 | 1982-11-30 | Schering Corporation | Treatment of peptic ulcer disease |
US4588732A (en) * | 1982-12-21 | 1986-05-13 | Ciba-Geigy Corporation | Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors |
US4470986A (en) * | 1982-12-21 | 1984-09-11 | Ciba-Geigy Corporation | Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors |
-
1984
- 1984-06-20 US US06/622,421 patent/US4617307A/en not_active Expired - Lifetime
-
1985
- 1985-06-17 DE DE8585810279T patent/DE3582452D1/de not_active Expired - Lifetime
- 1985-06-17 FI FI852399A patent/FI80694C/sv not_active IP Right Cessation
- 1985-06-17 AT AT85810279T patent/ATE62415T1/de not_active IP Right Cessation
- 1985-06-17 EP EP85810279A patent/EP0165904B1/de not_active Expired - Lifetime
- 1985-06-18 DZ DZ850130A patent/DZ799A1/fr active
- 1985-06-18 GR GR851487A patent/GR851487B/el unknown
- 1985-06-18 CA CA000484263A patent/CA1276633C/en not_active Expired - Lifetime
- 1985-06-18 IL IL75546A patent/IL75546A/xx not_active IP Right Cessation
- 1985-06-18 CS CS854449A patent/CS268672B2/cs not_active IP Right Cessation
- 1985-06-19 MA MA20686A patent/MA20459A1/fr unknown
- 1985-06-19 IE IE152085A patent/IE58070B1/en not_active IP Right Cessation
- 1985-06-19 HU HU852417A patent/HU202529B/hu unknown
- 1985-06-19 DK DK277685A patent/DK170302B1/da not_active IP Right Cessation
- 1985-06-19 NO NO852474A patent/NO162467C/no unknown
- 1985-06-19 ZA ZA854615A patent/ZA854615B/xx unknown
- 1985-06-19 ES ES544344A patent/ES8702406A1/es not_active Expired
- 1985-06-19 BG BG70749A patent/BG60262B2/xx unknown
- 1985-06-19 PH PH32427A patent/PH23390A/en unknown
- 1985-06-19 SU SU853917403A patent/SU1433413A3/ru active
- 1985-06-19 NZ NZ212483A patent/NZ212483A/xx unknown
- 1985-06-19 KR KR1019850004323A patent/KR900008566B1/ko not_active IP Right Cessation
- 1985-06-19 PT PT80661A patent/PT80661B/pt unknown
- 1985-06-19 AU AU43857/85A patent/AU589565B2/en not_active Expired
- 1985-06-19 RO RO85119210A patent/RO92583A/ro unknown
- 1985-06-20 PL PL1985259305A patent/PL145814B1/pl unknown
- 1985-06-20 PL PL1985259303A patent/PL145103B1/pl unknown
- 1985-06-20 PL PL1985254099A patent/PL145087B1/pl unknown
- 1985-06-20 DD DD85277587A patent/DD237510A5/de not_active IP Right Cessation
- 1985-06-20 PL PL1985259307A patent/PL145105B1/pl unknown
- 1985-06-20 JP JP60133167A patent/JPS6112688A/ja active Granted
- 1985-06-20 PL PL1985259304A patent/PL145348B1/pl unknown
- 1985-06-20 PL PL1985259306A patent/PL145104B1/pl unknown
-
1986
- 1986-05-30 ES ES555538A patent/ES8802048A1/es not_active Expired
- 1986-05-30 ES ES555539A patent/ES8802155A1/es not_active Expired
- 1986-05-30 ES ES555541A patent/ES8800681A1/es not_active Expired
- 1986-05-30 ES ES555540A patent/ES8801262A1/es not_active Expired
- 1986-05-30 ES ES555542A patent/ES8802049A1/es not_active Expired
- 1986-07-02 SU SU864027755A patent/SU1436879A3/ru active
- 1986-07-02 SU SU864027758A patent/SU1443802A3/ru active
- 1986-07-02 SU SU864027754A patent/SU1436878A3/ru active
- 1986-07-02 SU SU864027757A patent/SU1436880A3/ru active
- 1986-07-02 SU SU864027756A patent/SU1482530A3/ru active
-
1992
- 1992-06-25 MX MX9203369A patent/MX9203369A/es unknown
- 1992-10-22 BG BG97012A patent/BG60352B2/bg not_active Expired - Lifetime
- 1992-10-22 BG BG97011A patent/BG60307B2/xx unknown
- 1992-10-22 BG BG97010A patent/BG60306B2/bg unknown
- 1992-10-22 BG BG97009A patent/BG60305B2/bg unknown
- 1992-10-22 BG BG97013A patent/BG60353B2/bg unknown
-
1993
- 1993-11-11 BG BG98213A patent/BG60402B2/bg unknown
-
1994
- 1994-03-17 HK HK234/94A patent/HK23494A/xx not_active IP Right Cessation
- 1994-06-03 CY CY175094A patent/CY1750A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI80694B (fi) | Foerfarande foer framstaellning av teraoeutiskt aktiva 5,6,7,8-tetrahydroimidazo/1,5-a/pyridiner. | |
JP6789995B2 (ja) | Nrf2レギュレーター | |
AU2016280236B2 (en) | Nrf2 regulators | |
KR101972719B1 (ko) | 안드로겐 수용체 조절제 및 이의 용도 | |
RU2734760C2 (ru) | Противоинфекционные соединения | |
CA2943363A1 (en) | Anti-fibrotic pyridinones | |
CZ2002613A3 (cs) | Tricyklické inhibitory poly(ADP-ribózových) polymeráz | |
SK736887A3 (en) | Substituted imidazolyl- or 1,2,4-triazolylmethylbenzonitriles and a method for producing the same | |
HU196792B (en) | Process for producing 3,3-disubstituted indolin derivatives and pharmaceutical compositions containing them | |
EP1988091A1 (en) | Tricyclic compounds | |
MX2014011373A (es) | Inhibidores de diacilglicerol aciltransferasa 2. | |
JP2004526769A (ja) | 子宮収縮抑制オキシトシン受容体拮抗薬としての新規三環系ピリジルベンズアゼピンカルボキサミドおよびその誘導体 | |
CN109689656B (zh) | 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途 | |
US9266880B2 (en) | Substituted azaindazole compounds | |
US6159989A (en) | Antagonists of gonadotropin releasing hormone | |
JP2004527537A (ja) | 子宮収縮抑制オキシトシン受容体拮抗薬としての新規三環系ヒドロキシカルボキシアミド及びその誘導体 | |
AU2011336217B2 (en) | KAT II inhibitors | |
CZ20011981A3 (cs) | Sulfonamidové sloučeniny | |
NO140012B (no) | Analogifremgangsmaate for fremstilling av nye terapeutisk aktive derivater av naftyridin | |
CN113754635A (zh) | 稠环类化合物及其制备方法和用途 | |
JP2021512942A (ja) | トリアゾール、イミダゾールおよびピロール縮合ピペラジン誘導体、およびmGlu5受容体のモジュレータとしてのそれらの使用 | |
FI83079B (fi) | Foerfarande foer framstaellning av terapeutiskt aktiva 5-fenyl-imidazo/1,5-a/ pyridiner. | |
JP2018523660A (ja) | ベンゾジアゼピン誘導体の合成 | |
JPS59141580A (ja) | インド−ル誘導体 | |
WO2002094832A1 (en) | New benzylaminopyrimidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer of assignment of patent |
Owner name: NOVARTIS AG |
|
FG | Patent granted |
Owner name: NOVARTIS AG |
|
MA | Patent expired |